Abstract 125P
Background
BTC is a diverse group of hepatic and perihepatic malignancies with a 5-year survival rate of <20%. This study described real-world treatment patterns and outcomes among patients with advanced and/or unresectable (aBTC) in France, Germany, Italy, Spain, and the United Kingdom (UK).
Methods
In this retrospective, web-based chart review survey, physicians reported anonymized patient-level data for adult patients diagnosed with aBTC between May 2018 and October 2021 who received first-line (1L) systemic therapy (index date). Patients were followed from index date until death or last available date at abstraction. Patient characteristics, treatment patterns, and clinical outcomes were summarized descriptively.
Results
A total of 196 physicians extracted data for 792 aBTC patients who initiated 1L systemic therapy. More patients had intrahepatic cholangiocarcinoma (CCA; 34.8%), than extrahepatic CCA (29.9%), gallbladder (23.5%), and ampullary cancer (10.2%) whereas 1.5% patients had missing information. During follow-up (median=12.4 months), less than half of patients were prescribed gemcitabine + cisplatin (GemCis; 47.9%) as 1L. Median 1L treatment duration was 5.3 months with disease progression (49.2%) being the most common reason for treatment discontinuation. Only 33.1% received 2L and 4.1% received 3L+ of treatment. Median real-world overall survival (rwOS) from index date was 13.4 months, with regional variation (Table).
Table: 125P
Key results by country*
France (N = 167) | Germany (N = 150) | Italy (N = 153) | Spain (N = 167) | UK (N = 155) | |
Male, % | 67.1 | 66.7 | 55.6 | 65.9 | 57.4 |
Age ≥60, % | 73.1 | 60.7 | 76.5 | 76.0 | 85.2 |
Site of primary BTC tumor, % | |||||
Intrahepatic CCA | 31.1 | 35.3 | 51.0 | 28.7 | 29.0 |
Extrahepatic CCA | 30.5 | 28.0 | 26.8 | 29.3 | 34.8 |
Gallbladder | 23.4 | 29.3 | 11.1 | 28.7 | 24.5 |
Ampulla of Vater | 13.8 | 6.0 | 9.8 | 13.2 | 7.7 |
Unknown | 1.2 | 1.3 | 1.3 | 0 | 3.9 |
ECOG at diagnosis, % | |||||
0 | 20.4 | 14.7 | 27.5 | 18.6 | 32.9 |
1 | 52.1 | 48.0 | 64.1 | 67.7 | 52.3 |
2+ | 22.2 | 22.0 | 8.5 | 11.4 | 11.6 |
Unknown | 5.4 | 15.3 | 0 | 2.4 | 3.2 |
GemCis 1L regimen, % | 28.7 | 30.0 | 69.9 | 44.3 | 67.7 |
Median rwOS (months) | 17.8 | 18.3 | 14.7 | 13.1 | 8.8 |
*All decimals have been rounded to the nearest tenth, thus the overall % may result in getting a value slightly higher than 100%.
Conclusions
This study demonstrated the unmet needs of patients with aBTC, with less than half of the patients receiving standard-of-care – GemCis (ESMO recommendation) and a median rwOS of just over one year suggesting the need for new treatments that extend survival. With the recent approval of immunotherapy for aBTC patients, exploration of the benefits in real-world is needed. Additional efforts in the earlier detection of BTC are essential to improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J.A. Bridgewater: Financial Interests, Personal, Advisory Board: Taiho, BMS, Incyte, Basilea, Servier; Financial Interests, Institutional, Funding: Incyte. M. Paskow: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Szende: Financial Interests, Personal, Full or part-time Employment: Labcorp Drug Development; Financial Interests, Personal, Stocks/Shares: Labcorp Drug Development. P. Messina: Financial Interests, Personal, Full or part-time Employment: Labcorp, IQVIA. J. Sah: Financial Interests, Personal, Stocks/Shares: AstraZeneca; Financial Interests, Personal, Full or part-time Employment: AstraZeneca. B. Baur: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17